Biofrontera (NASDAQ:BFRI) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Biofrontera (NASDAQ:BFRI) to a hold rating in a research note released on Saturday morning.

Other research analysts also recently issued research reports about the company. Weiss Ratings raised Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. Zacks Research downgraded shares of Biofrontera from a “hold” rating to a “strong sell” rating in a research report on Friday, July 3rd. One analyst has rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Reduce”.

Biofrontera Stock Down 3.7%

Shares of BFRI opened at $1.05 on Friday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.09 and a current ratio of 1.20. Biofrontera has a 52 week low of $0.55 and a 52 week high of $1.21. The stock has a market capitalization of $13.44 million, a price-to-earnings ratio of -1.08 and a beta of 0.81. The stock has a fifty day moving average of $0.97 and a 200-day moving average of $0.93.

Biofrontera (NASDAQ:BFRI) last issued its earnings results on Thursday, May 14th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.29). The firm had revenue of $10.08 million during the quarter, compared to analyst estimates of $10.25 million. Biofrontera had a negative return on equity of 515.34% and a negative net margin of 25.66%. As a group, sell-side analysts anticipate that Biofrontera will post -0.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Biofrontera

A hedge fund recently raised its position in Biofrontera stock. Geode Capital Management LLC lifted its stake in shares of Biofrontera Inc. (NASDAQ:BFRI) by 54.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 65,677 shares of the company’s stock after acquiring an additional 23,074 shares during the quarter. Geode Capital Management LLC owned approximately 0.56% of Biofrontera worth $37,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 10.08% of the stock is currently owned by hedge funds and other institutional investors.

About Biofrontera

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.